neues zockerfutter - 500 Beiträge pro Seite

[yesup]

wkn 883121 frankfurt. ohne kommentar. keine empfehlung von mir. ich habe diese aktie nicht und werde sie auch nicht kaufen. aber vielleicht bekomme ich ja so heraus was die überhaupt machen und warum der kurs doch recht üppig steigt. die wahrheit allerdings liegt nur irgendwo dort draußen...

[mansch]

Hallo Yesup,
hättest Du ruhig kaufen können, heute Nasdaq + ca. 40 %
ich hab den Artikel noch nicht komplett übersetzt...
Viel Spass, ach so ist aus Yahoo.

Tuesday February 22, 12:50 pm Eastern Time

Company Press Release

SOURCE: Pharmos Corporation

Pharmos Corporation Receives Patent for Tamoxifen
Analogs For the Treatment and Prevention of Cancer

ISELIN, N.J., Feb. 22 /PRNewswire/ -- Pharmos Corporation (Nasdaq: PARS - news) announced that it has received a
Notice of Allowance for a new patent from the U.S. Patent and Trademark Office with claims covering enhanced
anti-angiogenic activity of permanently charged derivatives of steroid hormones. The new patent defines additional therapeutic
applications for the use of charged derivatives of steroid hormone agonists and antagonists in the treatment or prevention of
cancer and angiogenesis.

The superior therapeutic profile of these novel charged compounds compared with conventional pharmaceuticals has been
demonstrated in animal studies at Pharmos. The enhanced beneficial effects of charged tamoxifen derivatives were obtained
also in the case of some cancers that are not related to estrogen receptors, such as pancreatic cancer and malignant melanoma.

Importantly, the charged tamoxifen derivatives of anti-estrogens have also displayed superior safety profiles compared to
tamoxifen in the central nervous system (CNS) and the uterus. Tamoxifen is a first line of defense today in breast cancer
therapy; however, it has been known to induce CNS-related side effects and may lead to development of uterine tumors in a
small percentage of treated patients.

``These novel drugs reflect the strength of our innovative drug design capabilities. We have made a solid commitment to extend
the Company`s technological base by broadening its developmental pipeline,`` said George Fink, Ph.D., Vice President of
Research.

The discovery and development of novel and more potent charged tamoxifen and other SERM derivatives is a consequence of
Pharmos` platform technology in which combinatorial chemistry and high through-put screening are combined. Based on
state-of-the-art robotics, a large library of charged SERM derivatives and other enhanced molecular structures have been
synthesized and are being investigated at Pharmos for their ability to block angiogenesis and tumor growth. Angiogenesis is a
complex process in which there is new growth of capillary blood vessels in solid tumors, such as cancer of the breast, prostate
and pancreas.

Pharmos Corporation is a bio-pharmaceutical company that develops and commercializes products for the ophthalmic, central
nervous system, neurological and other key healthcare markets. The Company has a diverse product pipeline that includes:
marketed products with superior therapeutic indexes, and drug candidates with enhanced molecular structures that display
improved safety and/or efficacy properties compared to the parent molecules or to competing products.

Statements made in this press release related to the future beneficial expectations of the Company are considered
``forward-looking`` and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such
statements involve risks and uncertainties which may cause results to differ materially from those set forth in these statements.
Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos` filings with
the Securities and Exchange Commission could affect such results.